287 related articles for article (PubMed ID: 34728041)
1. [Nucleotide-binding Oligomerization Domain-like Receptor Family Pyrin Domain Containing 3 Inflammasome in Alzheimer's Disease].
Feng YY; Chen H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):788-795. PubMed ID: 34728041
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer's Disease.
Zhang Y; Zhao Y; Zhang J; Yang G
Neurochem Res; 2020 Nov; 45(11):2560-2572. PubMed ID: 32929691
[TBL] [Abstract][Full Text] [Related]
3. Microglial TLR4/NLRP3 Inflammasome Signaling in Alzheimer's Disease.
Li Y; Chen X; Zhou M; Feng S; Peng X; Wang Y
J Alzheimers Dis; 2024; 97(1):75-88. PubMed ID: 38043010
[TBL] [Abstract][Full Text] [Related]
4. A Novel Inhibitor Targeting NLRP3 Inflammasome Reduces Neuropathology and Improves Cognitive Function in Alzheimer's Disease Transgenic Mice.
Kuwar R; Rolfe A; Di L; Blevins H; Xu Y; Sun X; Bloom GS; Zhang S; Sun D
J Alzheimers Dis; 2021; 82(4):1769-1783. PubMed ID: 34219728
[TBL] [Abstract][Full Text] [Related]
5. Myricetin improves pathological changes in 3×Tg-AD mice by regulating the mitochondria-NLRP3 inflammasome-microglia channel by targeting P38 MAPK signaling pathway.
Liu P; Zhou Y; Shi J; Wang F; Yang X; Zheng X; Wang Y; He Y; Xie X; Pang X
Phytomedicine; 2023 Jul; 115():154801. PubMed ID: 37086707
[TBL] [Abstract][Full Text] [Related]
6. Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice.
Feng J; Wang JX; Du YH; Liu Y; Zhang W; Chen JF; Liu YJ; Zheng M; Wang KJ; He GQ
CNS Neurosci Ther; 2018 Dec; 24(12):1207-1218. PubMed ID: 29869390
[TBL] [Abstract][Full Text] [Related]
7. Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases.
Wu AG; Zhou XG; Qiao G; Yu L; Tang Y; Yan L; Qiu WQ; Pan R; Yu CL; Law BY; Qin DL; Wu JM
Ageing Res Rev; 2021 Jan; 65():101202. PubMed ID: 33161129
[TBL] [Abstract][Full Text] [Related]
8. Activation of NLRP3 Inflammasome and Onset of Alzheimer's Disease.
Bai H; Zhang Q
Front Immunol; 2021; 12():701282. PubMed ID: 34381452
[TBL] [Abstract][Full Text] [Related]
9. Targeting NLRP3-Mediated Neuroinflammation in Alzheimer's Disease Treatment.
Barczuk J; Siwecka N; Lusa W; Rozpędek-Kamińska W; Kucharska E; Majsterek I
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012243
[TBL] [Abstract][Full Text] [Related]
10. NLRP3 Inflammasome: An Emerging Therapeutic Target for Alzheimer's Disease.
Tao S; Fan W; Liu J; Wang T; Zheng H; Qi G; Chen Y; Zhang H; Guo Z; Zhou F
J Alzheimers Dis; 2023; 96(4):1383-1398. PubMed ID: 37980662
[TBL] [Abstract][Full Text] [Related]
11. The involvement of NLRP3 inflammasome in the treatment of Alzheimer's disease.
Feng YS; Tan ZX; Wu LY; Dong F; Zhang F
Ageing Res Rev; 2020 Dec; 64():101192. PubMed ID: 33059089
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease.
Severini C; Barbato C; Di Certo MG; Gabanella F; Petrella C; Di Stadio A; de Vincentiis M; Polimeni A; Ralli M; Greco A
Curr Neuropharmacol; 2021; 19(4):498-512. PubMed ID: 32564756
[TBL] [Abstract][Full Text] [Related]
13. Beta-amyloid activates NLRP3 inflammasome via TLR4 in mouse microglia.
Liu Y; Dai Y; Li Q; Chen C; Chen H; Song Y; Hua F; Zhang Z
Neurosci Lett; 2020 Sep; 736():135279. PubMed ID: 32726591
[TBL] [Abstract][Full Text] [Related]
14. TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease.
Yang J; Wise L; Fukuchi KI
Front Immunol; 2020; 11():724. PubMed ID: 32391019
[TBL] [Abstract][Full Text] [Related]
15. The Role of NLRP3 Inflammasome in Alzheimer's Disease and Potential Therapeutic Targets.
Liang T; Zhang Y; Wu S; Chen Q; Wang L
Front Pharmacol; 2022; 13():845185. PubMed ID: 35250595
[TBL] [Abstract][Full Text] [Related]
16. Soluble Aβ oligomers and protofibrils induce NLRP3 inflammasome activation in microglia.
Lučiūnaitė A; McManus RM; Jankunec M; Rácz I; Dansokho C; Dalgėdienė I; Schwartz S; Brosseron F; Heneka MT
J Neurochem; 2020 Dec; 155(6):650-661. PubMed ID: 31872431
[TBL] [Abstract][Full Text] [Related]
17. A novel strategy for bioactive natural products targeting NLRP3 inflammasome in Alzheimer's disease.
Yang Z; Liu J; Wei S; Deng J; Feng X; Liu S; Liu M
Front Pharmacol; 2022; 13():1077222. PubMed ID: 36699095
[TBL] [Abstract][Full Text] [Related]
18. NLRP3 and Infections: β-Amyloid in Inflammasome beyond Neurodegeneration.
Sita G; Graziosi A; Hrelia P; Morroni F
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209586
[TBL] [Abstract][Full Text] [Related]
19. NLRP3 Inflammasome: A Starring Role in Amyloid-β- and Tau-Driven Pathological Events in Alzheimer's Disease.
Van Zeller M; Dias D; Sebastião AM; Valente CA
J Alzheimers Dis; 2021; 83(3):939-961. PubMed ID: 34366341
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer's disease.
Thawkar BS; Kaur G
J Neuroimmunol; 2019 Jan; 326():62-74. PubMed ID: 30502599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
